Clinical Trial Update: Clinical Study of Neflamapimod in Patients With Primary Progressive Aphasia [Phase 2]

View source ↗

Summary

Phase 2 clinical trial of neflamapimod in nonfluent variant primary progressive aphasia is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Nonfluent Variant Primary Progressive Aphasia
• Progressive Aphasia

Drugs mentioned

• Neflamapimod (neflamapimod)

Snippet

Sponsor: EIP Pharma Inc | Conditions: Nonfluent Variant Primary Progressive Aphasia (nfvPPA) | Phase 2 | Status: RECRUITING